Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
|Videos|December 15, 2017
The Race to Develop a Safe & Effective C. difficile Vaccine
Author(s)Contagion® Editorial Staff
Richard Haupt, MD, MPH, discusses the different pharmaceutical companies’ efforts to develop a C. difficile vaccine.
Advertisement
Richard Haupt, MD, MPH, vice president of Medical Development at Pfizer Vaccines, discusses the different pharmaceutical companies’ efforts to develop a C. difficile vaccine.
Interview Transcript (modified slightly for readability):
“Are there other companies that are developing C. difficile vaccine? Yes, there are. Another major pharmaceutical vaccine maker Sanofi Pasteur is also in a phase 3 trial to assess the safety and efficacy of vaccines. And so, we, and Sanofi, are both trying to do the same thing, taking the same approach. The vaccine might be a little bit different but they’re both vaccines that are targeted against the toxins that mediate the disease.”
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
SubscribeAdvertisement
Related to this article
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Advertisement
Advertisement